Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system

References

• Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49(Suppl 1):43–51. doi:10.1080/10428190802311441. PMID:18821432.
   PubMed Web of Science ®Google Scholar
• Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008;111:3200–10. doi:10.1182/blood-2007-10-119099. PMID:18184868.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716–23. doi:10.1182/blood-2005-03-0897. PMID:16418334.
   PubMed Web of Science ®Google Scholar
• Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, Suh YL, Kim SH, Kim JY, Kim SJ, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood. 2011;117:1291–300. doi:10.1182/blood-2010-07-297861. PMID:21088137.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K. Primary central nervous system lymphoma: an update. Curr Opin Oncol. 2009;21:550–8. doi:10.1097/CCO.0b013e3283310eb3. PMID:19684518.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; 127:869–81. doi:10.1182/blood-2015-10-673236. PMID:26702065.
   PubMed Web of Science ®Google Scholar
• Langner-Lemercier S, Houillier C, Soussain C, Ghesquieres H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-oncology. 2016;18:1297–303. doi:10.1093/neuonc/now033. PMID:26951382.
   PubMed Web of Science ®Google Scholar
• Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203–20. doi:10.1038/nrclinonc.2016.168. PMID:27805626.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3. doi:10.1182/blood-2017-01-764209. PMID:28356247.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Restifo NP. Cellular Constituents of Immune Escape within the Tumor Microenvironment. Cancer Res. 2012;72:3125–30. doi:10.1158/0008-5472.CAN-11-4094. PMID:22721837.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367–75. doi:10.1182/blood-2009-06-225326. PMID:19636060.
   PubMed Web of Science ®Google Scholar
• Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A, Alvarez R, da Silva MG, et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi- automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica. 2015;100:363–9. doi:10.3324/haematol.2014.110189. PMID:25425693.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8. doi:10.1038/nrc1256. PMID:14708027.
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73. doi:10.1189/jlb.0609385. PMID:19741157.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3(+) regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500. doi:10.1038/nri2785. PMID:20559327.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed Death-1-Positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637–50. doi:10.1158/1078-0432.CCR-09-2487. PMID:20068089.
   PubMed Web of Science ®Google Scholar
• Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, Kim DW, Heo DS, Kim CW. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol. 2009;20:1688–96. doi:10.1093/annonc/mdp056. PMID:19542249.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–64. doi:10.1182/blood-2006-04-018218. PMID:16825494.
   PubMed Web of Science ®Google Scholar
• Ahearne MJ, Bhuller K, Hew R, Ibrahim H, Naresh K, Wagner SD. Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. Virchows Arch. 2014;465:351–8. doi:10.1007/s00428-014-1615-5. PMID:25011996.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193–200. doi:10.3324/haematol.11702. PMID:18223287.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137–43. doi:10.1016/j.it.2012.10.001. PMID:23103127.
   PubMed Web of Science ®Google Scholar
• Platten M, Wick W, Van den Eynde BJ. Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion. Cancer Res. 2012;72:5435–40. doi:10.1158/0008-5472.CAN-12-0569. PMID:23090118.
   PubMed Web of Science ®Google Scholar
• Wilke CM, Zou WP. T lymphocytes to IDO(+) cells: check. Blood. 2011;117:2082–3. doi:10.1182/blood-2010-12-322172. PMID:21330479.
   PubMed Web of Science ®Google Scholar
• Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459–68. doi:10.1084/jem.20020121. PMID:12186838.
   PubMed Web of Science ®Google Scholar
• Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azurna M, Blazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117:2570–82. doi:10.1172/JCI31911. PMID:17710230.
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. 2013;33:13–21. doi:10.1038/jcbfm.2012.153. PMID:23072749.
   PubMed Web of Science ®Google Scholar
• Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2014;55:2466–76. doi:10.3109/10428194.2013.879713. PMID:24397616.
   PubMed Web of Science ®Google Scholar
• Nam SJ, Kim S, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK. An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. Leuk Lymphoma. 2016:1–5.
   Web of Science ®Google Scholar
• Chang C, Lin CH, Cheng AL, Medeiros LJ, Chang KC. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology. 2015;67:625–35. doi:10.1111/his.12706. PMID:25829022.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, Bea S, Gonzalez-Diaz M, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–5. doi:10.1038/nature10113. PMID:21642962.
   PubMed Web of Science ®Google Scholar
• Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26:440–6. doi:10.1200/JCO.2007.12.8298. PMID:18086798.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New Engl J Med. 2010;362:875–85. doi:10.1056/NEJMoa0905680.
   PubMed Web of Science ®Google Scholar
• Kadoch C, Dinca EB, Voicu R, Chen LJ, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, et al. Pathologic correlates of primary central nervous system lymphoma defined in an Orthotopic Xenograft Model. Clin Cancer Res. 2009;15:1989–97. doi:10.1158/1078-0432.CCR-08-2054. PMID:19276270.
   PubMed Web of Science ®Google Scholar
• Zheng X, Turkowski K, Mora J, Brune B, Seeger W, Weigert A, Savai R. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;18;8(29):48436–52. doi: 10.18632/oncotarget.17061. PMID:28467800.
   PubMedGoogle Scholar
• Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Ostling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15:2000–11. doi:10.1016/j.celrep.2016.04.084. PMID:27210762.
   PubMed Web of Science ®Google Scholar
• Liu XQ, Lu K, Feng LL, Ding M, Gao JM, Ge XL, Wang X. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. Leuk Lymphoma. 2014;55:405–14. doi:10.3109/10428194.2013.804917. PMID:23682557.
   PubMed Web of Science ®Google Scholar
• Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011;17:6985–91. doi:10.1158/1078-0432.CCR-11-1331. PMID:22068654.
   PubMed Web of Science ®Google Scholar
• Adikari SB, Lian H, Link H, Huang YM, Xiao BG. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol. 2004;138:230–6. doi:10.1111/j.1365-2249.2004.02585.x. PMID:15498031.
   PubMed Web of Science ®Google Scholar
• Maby-El Hajjami H, Ame-Thomas P, Pangault C, Tribut O, DeVos J, Jean R, Bescher N, Monvoisin C, Dulong J, Lamy T, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase. Cancer Res. 2009;69:3228–37. doi:10.1158/0008-5472.CAN-08-3000. PMID:19276371.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, Yamanaka R, Kajiwara K, Saito T, Kuratsu J, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 2011;51:93–9. doi:10.3960/jslrt.51.93. PMID:22104307.
   PubMedGoogle Scholar
• Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82. doi:10.1182/blood-2003-05-1545. PMID:14504078.
   PubMed Web of Science ®Google Scholar